Royalty Pharma plc (RPRX) Total Return Calculator with Dividends Reinvested

Royalty Pharma plc

Popular:

The total return for Royalty Pharma plc (RPRX) stock is +44.53% over the past 12 months. So far it's up 22.22% this year. The 5-year total return is +21.13%, meaning $10,000 invested in RPRX stock 5 years ago would be worth $12,113 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in RPRX 1 year ago, it would be worth $14,518 today — you'd have gained $4,518 with dividends reinvested.

With Dividends Reinvested$14,518+45.18%

Price Only (No DRIP)$14,184+41.84%

Dividend Boost+$3344 payments · +3.34% extra

Period2025-03-04 → 2026-03-03

Price

Total Return (DRIP)

Dividends

S&P 500

If You Invested $10,000 in RPRX

1Y$14,453+$4,453 (+44.5%)44.5% CAGR

3Y$14,172+$4,172 (+41.7%)12.3% CAGR

5Y$12,113+$2,113 (+21.1%)3.9% CAGR

10Y$11,631+$1,631 (+16.3%)1.5% CAGR

15Y$11,631+$1,631 (+16.3%)1.0% CAGR

20Y$11,630+$1,630 (+16.3%)0.8% CAGR

30Y$11,630+$1,630 (+16.3%)0.5% CAGR

Dividend Reinvestment History (4)▲ Hide

Ex-Date	Dividend	Reinvest Price	Shares Added
2025-05-16	$0.22	$34.02	+0.006467
2025-08-15	$0.22	$36.35	+0.006091
2025-11-14	$0.22	$39.16	+0.005689
2026-02-20	$0.23	$45.12	+0.005303

Loading RPRX total return...

As of 2026-03-04

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+22.22%	—	+21.62%	+0.60 pp	$12,222
1Y	+44.53%	44.53%	+41.84%	+2.69 pp	$14,453
3Y	+41.72%	12.33%	+34.45%	+7.27 pp	$14,172
5Y	+21.13%	3.91%	+11.62%	+9.51 pp	$12,113
10Y	+16.31%	1.52%	+6.20%	+10.10 pp	$11,631
15Y	+16.31%	1.01%	+6.20%	+10.10 pp	$11,631
20Y	+16.30%	0.76%	+6.20%	+10.10 pp	$11,630
30Y	+16.30%	0.50%	+6.20%	+10.10 pp	$11,630

Risk & Highlights

Best Year+53.24%2025

Worst Year-26.68%2023

Max Drawdown-8.89%2025-03-05 → 2025-04-08 · Recovered 2025-05-16

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	+19.52%	+18.91%	+0.6pp	+0.41%	+19.1pp
2025	+53.24%	+49.83%	+3.4pp	+16.64%	+36.6pp
2024	-6.79%	-9.76%	+3.0pp	+24.00%	-30.8pp
2023	-26.68%	-28.71%	+2.0pp	+24.81%	-51.5pp
2022	+2.49%	+0.56%	+1.9pp	-19.95%	+22.4pp

RPRX outperformed the S&P 500 by 26.59pp over the past year (+44.53% vs +17.94%).

Loading summary...

RPRX Peers' Total Return

Biotechnology · Top 11 by market cap

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
RPRXRoyalty Pharma plc	$7.1B	+8.2%	+22.2%	+44.5%	+2.7pp	+41.7%	+21.1%	+16.3%
AGIOAgios Pharmaceuticals, Inc.	$2.11T	+2.5%	+4.4%	-15.0%	—	+17.4%	-40.0%	-36.0%
VRTXVertex Pharmaceuticals Incorporated	$120.4B	+0.7%	+4.8%	-2.5%	—	+62.5%	+128.0%	+436.2%
REGNRegeneron Pharmaceuticals, Inc.	$107.4B	+0.7%	+0.7%	+16.1%	+0.5pp	+0.6%	+74.7%	+94.4%
ARGXargenx SE	$46.4B	-11.9%	-10.8%	+20.7%	—	+119.3%	+157.4%	+3159.3%
ALNYAlnylam Pharmaceuticals, Inc.	$42.2B	-9.3%	-20.3%	+31.4%	—	+59.8%	+132.3%	+439.2%
BNTXBioNTech SE	$25.4B	-7.1%	+4.5%	-7.8%	—	-23.2%	+8.4%	+624.5%
UTHRUnited Therapeutics Corporation	$22.0B	+4.5%	+1.6%	+63.5%	—	+103.4%	+214.6%	+295.2%
RVMDRevolution Medicines, Inc.	$19.9B	+4.9%	+28.1%	+166.7%	—	+306.0%	+138.5%	+250.4%
INCYIncyte Corporation	$19.6B	-3.7%	-2.6%	+41.7%	—	+30.2%	+27.4%	+37.2%
MRNAModerna, Inc.	$19.4B	+15.7%	+60.4%	+63.0%	—	-65.6%	-62.6%	+166.1%

Compare:RPRX vs AGIO RPRX vs VRTX RPRX vs REGN RPRX vs AGIO vs VRTX

About RPRX Dividend Returns

Royalty Pharma plc (RPRX) is a dividend-paying stock. When dividends are reinvested through a DRIP (Dividend Reinvestment Plan), they purchase additional shares, which then generate their own dividends—creating a compounding effect that can significantly boost long-term returns.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of RPRX over the past year?

Royalty Pharma plc (RPRX) delivered a total return of 44.53% over the past year when dividends are reinvested. The price-only return was 41.84%, meaning dividends contributed an additional 2.69 percentage points to total returns.

Q2How much would $10,000 invested in RPRX be worth today?

A $10,000 investment in Royalty Pharma plc one year ago would be worth $14,453 today with dividends reinvested (DRIP). Without reinvesting dividends, the same investment would be worth $14,184. Dividend reinvestment added $269 to the portfolio value.

Q3Does RPRX pay dividends?

Yes, Royalty Pharma plc (RPRX) pays dividends. In the last year, RPRX paid approximately $0.67 per share in dividends (1.42% yield). Reinvesting these dividends through a DRIP can significantly boost long-term returns — over 20+ years, dividend compounding can account for 30–50% of total returns for dividend-paying stocks.

Q4Did RPRX beat the S&P 500?

Yes, Royalty Pharma plc (RPRX) outperformed the S&P 500 by 26.59 percentage points over the past year. RPRX delivered a total return of 44.53%, compared to the S&P 500's 17.94%. This 26.59pp alpha means investors in RPRX earned more than a passive S&P 500 index fund.

Q5What is RPRX's worst drawdown?

Royalty Pharma plc (RPRX) experienced a maximum drawdown of -8.89% over the past year, declining from its peak on 2025-03-05 to its trough on 2025-04-08. The stock recovered to its prior peak by 2025-05-16. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is RPRX's long-term total return over 10, 20, or 30 years?

Royalty Pharma plc (RPRX) has delivered strong long-term returns with dividends reinvested. Over 10 years, the total return is 16.3% (1.5% CAGR) — $10,000 would have grown to $11,631. Over 20 years: 16.3% total return (0.8% CAGR) — $10,000 → $11,630. Over 30 years: 16.3% total return (0.5% CAGR) — $10,000 → $11,630. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was RPRX's best and worst year?

Royalty Pharma plc's best calendar year was 2025 with a total return of 53.2%. Its worst year was 2023 with a total return of -26.7%. This range shows the volatility investors should expect — the difference between the best and worst year is 79.9 percentage points.